Tune into candid conversations among professionals in companion diagnostics, an important field in the world of precision medicine. Blending expertise with real-world experience across multiple disciplines, this series aims to illuminate the challenges, approaches, and latest perspectives in companion diagnostics through thoughtful and educational dialogue.
Episode 10: Biomarker Testing in Ovarian Cancer - From Companion Diagnostics to Clinical Decision-Makingode 10 - US episodes
Episode 10 of the “Dialogues in CDx” podcast series focuses on the practical aspects of biomarker testing in ovarian cancer and its growing role in treatment decision-making. The discussion explores testing workflows, reflex versus on-demand testing, tissue selection, re-biopsy considerations, and assay validation. The speakers highlight the importance of collaboration between oncologists and pathologists, discuss current challenges in biomarker interpretation, and look ahead to emerging biomarkers and future innovations in precision oncology.
Dr. Brooke Howitt is a gynecologic and sarcoma pathologist at Stanford University whose clinical and research interests focus on gynecologic neoplasms, including the molecular alterations that influence diagnosis, classification, andbiomarker-driven patient care.
Our second guest, Dr. Bradley Monk, is a board-certified gynecologic oncologist with Florida Cancer Specialists & Research Institute. He has led and contributed to numerous practice-changing clinical trials in gynecologic cancers and iswidely recognized for his work advancing precision medicine and novel therapies for women with gynecologic malignancies.
This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay.
For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's CDx Digital Education Portal (https://bit.ly/3YTTOOk) today.
D0151977_1.00
10 Sept 2026
Episode 9: Advances in Ovarian Cancer - New Therapies for Platinum-Resistant Disease
This episode explores how precision medicine is transforming ovarian cancer care. The discussion covers the challenges of treating advanced and platinum-resistant ovarian cancer, recent advances in targeted therapies and immunotherapy, and the growing impact of biomarker-driven treatment selection. The speakers also examine the role of companion diagnostics, particularly PD-L1 and FRα testing, and how these tools are helping clinicians personalize treatment and expand options for patients.
Dr. Brooke Howitt is a gynecologic and sarcoma pathologist at Stanford University whose clinical and research interests focus on gynecologic neoplasms, including the molecular alterations that influence diagnosis, classification, and biomarker-driven patient care.
Our second guest, Dr. Bradley Monk, is a board-certified gynecologic oncologist with Florida Cancer Specialists & Research Institute. He has led and contributed to numerous practice-changing clinical trials in gynecologic cancers and is widely recognized for his work advancing precision medicine and novel therapies for women with gynecologic malignancies.
This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay.
For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's CDx Digital Education Portal (https://bit.ly/3YTTOOk) today.
D0151976_1.00
16 Jul 2026
Episode 8: PD L1 and Beyond in Head & Neck Cancer - Innovation, AI, and What Comes Next
In the eighth episode of Agilent’s Dialogues in CDx, our guests from episode 7 continue the conversation on head and neck cancers with a more forward‑looking perspective. Building on the discussion of current practice, this episode explores what lies ahead—from emerging biomarkers and AI‑enabled pathology to the challenges and opportunities shaping the future of precision care in HNSCC.
Professor Cécile Badoual is a pathologist and Head ofthe Department of Medical Biology and Pathology at Gustave Roussy in Paris. An expert in head and neck cancers, her research focuses on the tumor microenvironment of HPV‑associated cancers. Beyond her current roles, she has held numerous senior academic and institutional leadership positions, and her career has been recognized with several prestigious honors for her contributions to pathology and translational cancer research.
Our second guest, Dr. Marc Oliva, is a medical oncologist and clinician‑scientist with a focus on head and neck malignancies and early drug development. He trained at Princess Margaret Cancer Centre in Toronto and is currently a full consultant at the Catalan Institute of Oncology in Barcelona. Dr. Marc Oliva has an established record of peer‑reviewed scientific publications and is actively engaged in the scientific publishing process as an editor and regular reviewer for leading international oncology and immunology journals.
This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay.
For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's CDx Digital Education Portal (https://bit.ly/3YTTOOk) today.
D0147438_1.00
29 May 2026
Episode 7: PD-L1 Testing in Head & Neck Cancer - Current Practice and Clinical Impact
In Episode 7 of Agilent’s Dialogues in CDx, we turn our focus to recent advances in head and neck cancers, a field marked by rapid evolution in diagnostics and clinical decision‑making. To unpack what’s changing and why it matters for patient care, we welcome two specialists at the forefront of this space, offering complementary insights from pathology and oncology.
Professor Cécile Badoual is a pathologist and Head of the Department of Medical Biology and Pathology at Gustave Roussy in Paris. An expert in head and neck cancers, her research focuses on the tumor microenvironment of HPV‑associated cancers. Beyond her current roles, she has held numerous senior academic and institutional leadership positions, and her career has been recognized with several prestigious honors for her contributions to pathology and translational cancer research.
Our second guest, Dr. Marc Oliva, is a medical oncologist and clinician‑scientist with a focus on head and neck malignancies and early drug development. He trained at Princess Margaret Cancer Centre in Toronto and is currently a full consultant at the Catalan Institute of Oncology in Barcelona. Dr. Marc Oliva has an established record of peer‑reviewed scientific publications and is actively engaged in the scientific publishing process as an editor and regular reviewer for leading international oncology and immunology journals.
This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay.
For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's CDx Digital Education Portal (https://bit.ly/3YTTOOk) today.
D0147437_1.00
26 Feb 2026
Episode 6: PD-L1 Prevalence - Reconciling clinical data with real world data
In episode number 6 of Agilent’s “Dialogues in CDx” podcast, we explore how to bridge the gap between clinical data and the realities of daily laboratory practice. To unpack this topic, we are joined by two distinguished experts who bring complementary perspectives from pathology and oncology.
Dr. Birgit Guldhammer Skov, consultant pathologist at the Department of Pathology, Sjaelland University Hospital in Denmark, works primarily with lung cancer. She has been involved in evaluating PD-L1 in lung cancer since the biomarker was introduced in 2016.
Our second guest, Professor Inge Marie Svane, is a consultant oncologist at the Department of Oncology at Herlev Hospital in Denmark and Director of the national “Center for Cancer Immune Therapy” (CCIT). She currently leads oncology care for melanoma patients in eastern Denmark and has a special interest in real-world data and new treatment strategies for anti-PD1 refractory patients.
This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay.
For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's CDx Digital Education Portal (https://bit.ly/3YTTOOk) today.
D0133061 _1.00
15 Nov 2025
Episode 5: Interpretation of CDx markers - How do we ensure proper training?
In the fifth episode of Agilent’s “Dialogues in CDx” podcast, we discuss how to ensure proper training for PD-L1 interpretation. Two leaders who are shaping this space discuss why training is important, the best practices, and how it impacts patient care.
The first guest in this episode is Dr. Bharat Jasani, Emeritus Professor in Cancer Pathology in the School of Medicine at Cardiff University. Dr. Jasani has been extensively involved in training of more than 1,000 pathologists worldwide in quality assurance and scoring, as well as interpretation of cancer biomarker expression, particularly PD-L1 and HER2.
Also joining the conversation is Karin Salomon who has worked for Agilent Technologies in R&D for more than 20 years as a principal microscopy expert. Karin is evaluating thousands of HER2 and PD-L1 stained slides every year and trains pathologists in scoring of various biomarkers through Agilent’s Biomarker Pathologist Training Program in Europe.
This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay.
For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's CDx Digital Education Portal (https://bit.ly/3YTTOOk) today.
D0133059 _1.00
In the fourth episode of the “Dialogues in CDx” podcast series, we explore the issue of sample limitations and how pathologists can address them when performing PD-L1 testing. Two leaders in gastrointestinal pathology join the host Scott W. Boyer in an engaging discussion of the main challenges and solution strategies. Dr. Mar Iglesias Coma is Head of the Pathology Department at Hospital del Mar in Barcelona and specializes in gastrointestinal pathology. Since 2008, Dr. Iglesias has served as an associate professor at the Faculty of Medicine in Pathology, and is a contributor to multiple innovation projects, particularly within the fields of digital pathology, tools for multidisciplinary tumor committees, biomarkers, and laboratory applications.
Also joining the conversation is Professor Manuel Rodriguez-Justo, a consultant in gastrointestinal pathology and haematopathology at University College London Hospitals as well as a Professor of Onco-Pathology at UCL-Cancer Institute. Professor Rodriguez-Justo has implemented molecular pathways and biomarker testing in gastrointestinal cancers and is involved in designing and developing multiple national and multicenter trials.
This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay.
For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's CDx Digital Education Portal (https://bit.ly/3YTTOOk) today.
D0131924 _1.00
15 Jul 2025
Episode 3: The Pathologist-Oncologist Connection - Optimal Reporting of the PD-L1 Results
In this third episode of the "Dialogues in CDx" podcast series, you’ll listen to the distinguished guests Dr. Phillippe Taniere and Dr. Shobhit Baijal once more. The previous episode dissected the PD-L1 testing journey from biopsy to report. This episode will focus on the topic of PD-L1 reporting: What information should the pathologist provide for the oncologist? What information helps the oncologist make the best treatment decisions?
As in the second episode, perspectives from both a pathologist and an oncologist are presented. Dr. Phillipe Taniere is a Consultant Histopathologist and Clinical Service Lead for Molecular Pathology at University Hospitals Birmingham in UK. Dr. Taniere’s department completed 20,000 CDx tests last year.
Also joining the discussion is Dr. Shobhit Baijal, a Consultant Medical Oncologist at the University Hospitals Birmingham NHS Trust and an Honorary Associate Professor at the University of Birmingham, where he specializes in the treatment of thoracic and colorectal malignancies. Dr. Baijal specializes in all forms of cancer therapy and is a UK Chief and Principal Investigator for National and International studies. He is also a steering committee member of the British Thoracic Oncology Group. His vast experience provides invaluable input to the discussion.
This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay.
For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent's CDx Digital Education Portal (https://bit.ly/3YTTOOk) today.
D0130749_1.00
20 May 2025
Episode 2: Resection to Report - The PD-L1 Testing Journey
Consultant Histopathologist Dr. Phillipe Taniere and Consultant Medical Oncologist Dr. Shobhit Baijal examine the PD-L1 testing journey, emphasizing turnaround times and oncologist-pathologist collaboration in this interview.
20 May 2025
Episode 1: A Look Behind the Scenes - Extracting Cutoff and Scoring Algorithms from Clinical Data Title
Pathologists Hans-Ulrich Schildhaus and Douglas Clark discuss the complexities of PD-L1 scoring algorithms and cutoffs with host Scott W. Boyer, examining their origins and application in clinical diagnostics in this interview.
13 May 2025
Trailer: Welcome to the "Dialogues in CDx" Podcast
Host Scott W. Boyer introduces the "Dialogues in CDx" podcast series, which explores challenges and solutions in companion diagnostics through expert discussions, offering insights for pathologists and oncologists in this interview.
Who has been a guest on Agilent “Dialogues in CDx” Podcast Series
Names identified in recent episode analyses. Showing up to five guests.
Dr Phillipe Taniere
Dr Shobhit Baijal
Hans-Ulrich Schildhaus
Douglas Clark
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Spotify
5.0 / 5
5 ratings
Podcast Authority Score: 3 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
6
Social presence
0
YouTube
0
Engagement
0
Host of Agilent “Dialogues in CDx” Podcast Series?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
